Shares of OKYO Pharma Limited (LON:OKYO – Get Free Report) traded down 24.3% on Thursday . The stock traded as low as GBX 1.40 ($0.02) and last traded at GBX 1.40 ($0.02). 364,142 shares traded hands during trading, a decline of 16% from the average session volume of 431,999 shares. The stock had previously closed at GBX 1.85 ($0.02).
OKYO Pharma Stock Performance
The company has a quick ratio of 2.65, a current ratio of 0.83 and a debt-to-equity ratio of 1.65. The firm has a 50-day moving average of GBX 1.40 and a two-hundred day moving average of GBX 1.40. The company has a market capitalization of £23.24 million, a PE ratio of -140.00 and a beta of -0.06.
OKYO Pharma Company Profile
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain.
Featured Articles
- Five stocks we like better than OKYO Pharma
- EV Stocks and How to Profit from Them
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Consumer Staples Stocks, Explained
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for OKYO Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OKYO Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
